Recombinant Human IL-28A/IFN-lambda 2 (HEK293) Protein

• Reactivity: Hu
• Applications: Bioactivity

Recombinant Human IL-28A/IFN-lambda 2 (HEK293) Protein Summary

• Details of Functionality: Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED₅₀ for this effect is 5-25 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human IL-28A/IFN-lambda 2 protein
  Val26-Val200
• Accession #: Q8IZJ0
• N-terminal Sequence: Val26 & Val28
• Protein/Peptide Type: Recombinant Proteins
• Gene: IFNL2
• Purity: >95%, by SDS-PAGE with silver staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 20 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 20-23 kDa, reducing condtions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Purity: >95%, by SDS-PAGE with silver staining
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-28A/IFN-lambda 2 (HEK293) Protein

• interleukin-28A
• IFN-lambda 2
• IL28A
• IL-28A
• interferon, lambda 2

Background

IL‑28A (Interferon-lambda 2; IFN-lambda 2), IL-28B/IFN-lambda 3, and IL-29/IFN-lambda 1 are type III interferons which are distantly related to IL-10 family and type I IFN family cytokines (1‑3). Mature human IL-28A is an approximately 22-25 kDa protein that shares 66% amino acid (aa) sequence identity with mouse and rat IL-28A and shows cross-species activity (4). It shares 96% and 70% aa sequence identity with human IL-28B and IL-29, respectively. Type III interferons are upregulated in response to viral infection, and they act predominantly on epithelial cells through a receptor complex that contains IL-10 R beta and IL-28 R alpha /IFN-gamma R1 (4-6). Type III IFNs function as anti-viral molecules and induce the upregulation of MHC class I antigen (4, 5, 7). IL-28A promotes the Th1 polarization of dendritic cells in the airway (e.g. production of IL-12 p70 and IFN-gamma ) and inhibits Th2 and Th17 mediated inflammation (8). In the liver, however, the IL-28A induced Th1 cytokine response contributes to inflammation in T cell mediated hepatitis (9). IL-28A additionally exhibits anti-tumor activity, in part by enhancing IL-12 dependent anti-tumor CTL responses in vivo (10-12). In contrast, it is up-regulated in invasive bladder cancer where it promotes tumor cell migration (13).

1. Durbin, R.K. et al. (2013) Immunol. Rev. 255:25.
2. Li, Q. et al. (2013) Front. Biosci. (Landmark Ed.) 18:909.
3. Lopusna, K. et al. (2013) Acta Virol. 57:171.
4. Ank, N. et al. (2006) J. Virol. 80:4501.
5. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
6. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
7. Pott, J. et al. (2011) Proc. Natl. Acad. Sci. USA 108:7944.
8. Koltsida, O. et al. (2011) EMBO Mol. Med. 3:348.
9. Siebler, J. et al. (2007) Gastroenterology 132:358.
10. Sato, A. et al. (2006) J. Immunol. 176:7686.
11. Tezuka, Y. et al. (2012) Lung Cancer 78:185.
12. Numasaki, M. et al. (2007) J. Immunol. 178:5086.
13. Lee, S.J. et al. (2012) PLoS ONE 7:e40267.

Publications for IL-28A/IFN-lambda 2 (8417-IL)(4)

Publications using 8417-IL

• Groen, K;Kuratli, R;Sar, L;Vasou, A;Huber, M;Hughes, DJ;Hale, BG; Highly sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodies European journal of immunology 2024-10-04 [PMID: 39367550] (Bioassay, Human)
• J Song, RD Chow, M Pena-Herna, L Zhang, SA Loeb, EY So, OD Liang, P Ren, S Chen, CB Wilen, S Lee LRRC15 inhibits SARS-CoV-2 cellular entry in trans PloS Biology, 2022-10-13;20(10):e3001805. 2022-10-13 [PMID: 36228039] (Bioassay, Human)
• JH Chung, SH Hong, N Seo, TS Kim, HJ An, P Lee, EC Shin, HM Kim Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency Cytokine, 2019-08-31;125(0):154833. 2019-08-31 [PMID: 31479875] (Bioassay, Human)
• AA Obajemu, N Rao, KA Dilley, JM Vargas, F Sheikh, RP Donnelly, RS Shabman, EG Meissner, L Prokunina-, OO Onabajo IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling J. Immunol., 2017-10-25;0(0):. 2017-10-25 [PMID: 29070670] (Bioassay, Human)

Bioinformatics

• Gene Symbol: IFNL2
• Uniprot:
  • Q8IZJ0()